Despite a high initial response rate to platinum/taxane-based therapy in patients with advanced ovarian cancer, the effectiveness of treatment diminishes over time, and most patients relapse.
Ovarian cancer is an avaricious tumor that can extend throughout the entire abdominal cavity. It is one of the most difficult diseases to diagnose and the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States.
Before the 2014 FDA approval of olaparib for the treatment of recurrent ovarian cancer in patients with germline BRCA mutation and the 2016 FDA approval of bevacizumab in combination with chemotherapy for platinum-resistant ovarian cancer, the last FDA approval in ovarian cancer was in the mid-2000s.
The July issue of The Oncology Nurse-APN/PA (TON) is packed with indispensable news and insights for today’s oncology nurse.
The Oncology Nurse-APN/PA spoke with Sandra Kurtin, PhDc, RN, MS, AOCN, ANP-C, a nurse practitioner who specializes in treating patients with hematologic malignancies at The University of Arizona Cancer Center as part of a multidisciplinary team.
According to D. Kathryn Tierney, PhD, RN, cancer survivors, patients, and their providers are not talking about the incidence of sexual dysfunction, which can have a negative impact on cancer survivors’ quality of life as well as their intimate partners.
Compassion is defined as a feeling of deep sorrow for another’s pain, accompanied by an equally powerful desire to lessen or remove their suffering, be it mental, physical, or emotional. The difference between empathy and compassion is action.
To sign up for our newsletter or print publications, please enter your contact information below.
